| ￥3000 | |
| Z05926-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 43.00 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 70-100 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of TrkA, His, Human is greater than 95% as determined by SEC-HPLC. »
TrkA, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | TrkA, a tyrosine kinase receptor, is an essential component of the nerve growth factor (NGF) response pathway. The binding of NGF to the receptor induces receptor autophosphorylation and activation of intracellular signaling pathways, resulting in diverse biological effects. |
| Synonyms | Trk-A; NTRK1; MTC; TRK; TRKA; TrkA-I; TrkA I; TrkAI |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
